BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:Therapeutic vaccines for cancer and the role of immunomodulatory d
 rugs - Professor Angus Dalgleish\, Consultant Medical Oncologist\, St. Geo
 rge’s University of London/St George’s Hospital NHS Trust
DTSTART:20101215T163000Z
DTEND:20101215T173000Z
UID:TALK28398@talks.cam.ac.uk
CONTACT:Suzy Blows
DESCRIPTION:Cancer vaccines have been in trials for decades but only this 
 year did the first one (for humans) get approved by the FDA. How come so m
 any good phase 2 studies fail to be repeated in a randomised phase 3 trial
 ? Data from a number of studies suggest that non responders are more likel
 y to have high inflammatory markers than responders and that these patient
 s should be excluded from such trials. Pre treatment with \nanti-inflammat
 ories may convert non responders to responders. Some of these drugs such a
 s the thalidomide analogues (Revlimid) and Gemzar have marked activity on 
 suppressor and regulatory cells. Other chemotherapy \nagents may also have
  favourable effects on the immune system and enhance vaccine responses and
  not inhibit them as previously thought.
LOCATION:Lecture Theatre 1\, Department of Veterinary Medicine
END:VEVENT
END:VCALENDAR